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ORIGINAL ARTICLE
Steroid Administration and Growth Impairment in Children with
Crohn’s Disease
Carl Frédéric Duchatellier, MD, MSc,*,† Rituanjali Kumar, MSc,* Alfreda Krupoves, MD, PhD,*
Christian Braegger, MD,‡ Denise Herzog, MD,‡ and Devendra K. Amre, MBBS, PhD*,§
Background: Growth impairment remains a major concern in children with Crohn’s disease, but evidence remains unclear, in particular, whether
steroid use is implicated. We aimed to (1) determine the frequency of temporary (TGI) and permanent (PGI) growth impairment in children administered
steroids and (2) examine whether cumulative steroid administration was associated with TGI and/or PGI.
Methods: A retrospective cohort study was performed in patients with Crohn’s disease (,18 yr) administered steroids at the gastroenterology clinics of
Sainte-Justine Hospital, Montreal. Steroid dosage, height during follow-up, adult height (after age 20), and parental heights were ascertained. Patients
with height z score,21.64 on more than 1 occasion before age 18 were considered as patients with TGI. Patients with adult heights ,8.5 cm below the
expected target heights were considered as patients with PGI. Association between steroid dosage and TGI/PGI was studied using logistic regression
analyses. Data from the Swiss IBD Cohort Study were analyzed for comparison.
Results: A total of 221 children were studied. Approximately 19% (42/221) children were deemed as TGI, and 8/137 patients (5.8%) had PGI. TGI was
associated with diagnosis at younger age (P value 0.002) and steroid administration at younger age (P value 0.001), but not with steroid dosage. Final
adult height was associated with target height, but not with cumulative steroid dosage. Rates of PGI in the Swiss cohort were ;9.1% in steroid users and
2.7% in nonusers.
Conclusions: Most children with TGI attain normal adult heights. Cumulative steroid use does not seem to be associated with either TGI or PGI in
children with Crohn’s disease.
(Inﬂamm Bowel Dis 2016;22:355–363)
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G rowth impairment is a major clinical challenge in childrendiagnosed with Crohn’s disease (CD). Rates of up to
80% have been reported.1–3 In many children, growth impair-
ment precedes the diagnosis of disease. Whether this impair-
ment is related to the disease process itself or to other
unknown risk factors is currently unclear. In a number
of children, however, growth impairment develops during
the disease course. This impairment is suggested to be due
to a complex interplay between nutritional-, inﬂammation-,
hormonal-, and treatment-related factors. A key question is,
however, whether growth impairment observed during the
disease process leads to failure to achieve normal adult height.
Evidence regarding the occurrence of permanent growth impair-
ment (PGI) is, however, currently inconsistent. Although some
studies indicate that PGI is common,4,5 others suggest other-
wise.6–8 Disease heterogeneity, variability in measures used to
classify the growth impairment phenotype, and lack of account-
ing for genetic effects on growth may have resulted in these
discrepant results. In this context, recently, using parental
heights, Lee et al9 showed that indeed the ﬁnal adult heights of
children with CD are strongly related to parental heights and that
only ;11% of children had persistent growth impairment or PGI
in adulthood. This study highlights the importance of an appro-
priate classiﬁcation of the growth impairment phenotype in chil-
dren with CD.
Steroids are the mainstay in the treatment of CD in children.
Numerous studies have demonstrated that steroid use can
inﬂuence linear growth in children.7 These effects are believed
to be mediated through the growth hormone–insulin factor 1
axis.3,10 Although there is considerable biological data, epidemi-
ological evidence of the impact of steroid use and growth impair-
ment in children with CD remains limited and controversial.
Although some studies suggest a detrimental effect on growth,5,8
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others do not support this relationship.9 Furthermore, some studies
have shown that although steroid use may result in temporary
growth impairment (TGI), many children demonstrate catch-up
growth such that their ﬁnal adult heights are within reference
ranges.6,8,11 The major limitation of previous studies is the lack
of comprehensive data on steroid use and the inability to adjust
for other potential risk factors (disease activity, for example) that
could inﬂuence growth independently of steroid usage. To further
clarify the role of steroids in TGI and PGI, we performed
a detailed study on a cohort of children who were administered
steroids and in who we used parental heights to deﬁne the PGI
phenotype.
METHODS
This study was based on a recent retrospective cohort study
that investigated the burden and predictors of steroid resistance and
dependence in children with CD.12 It was performed at the gastro-
enterology clinic of Sainte-Justine Hospital (SJH), Montreal.
Patients were children ,18 years of age diagnosed with CD using
standard clinical, histological, radiological, and endoscopic crite-
ria.13,14 The medical records of these children diagnosed between
the years 1980 and 2007 were retrospectively reviewed to identify
patients who received corticosteroids since diagnosis. Clinical de-
tails, such as disease characteristics (location and behavior) at
diagnosis, corticosteroid therapy, concomitant medication, extrain-
testinal manifestations, surgeries, and family history of inﬂamma-
tory bowel disease (IBD), were abstracted. Pubertal stage was not
available for most patients. Boys below the age of 13 and girls
below the age or 11 were considered prepubertal. Information on
racial and ethnic background was acquired by administering a sup-
plementary questionnaire. CD was classiﬁed according to the
World Gastroenterology Organization’s Montreal classiﬁcation.15
Concomitant medication for the purpose of this study was consid-
ered if it was introduced during initial corticosteroid therapy before
the start of corticosteroid tapering and not if it was given in
response to disease relapse. Disease severity was assessed using
a modiﬁed Harvey–Bradshaw index.16 The only modiﬁcation made
to the original index was that the average number of stools during
a 24-hour period was assigned scores as follows: none ¼ 0; 1 to 2
¼ 1; 3 to 4 ¼ 2; 5 to 7 ¼ 3; 8 to 9 ¼ 4; $10 ¼ 5.
For corticosteroid use, we abstracted data on the following:
1. Age at which steroids were ﬁrst introduced
2. Dose of steroid administered (milligram/day using recorded
weights)
3. Duration (days)
4. Modiﬁcations of dosage if any
5. Number of steroid courses
6. Type of steroid
7. Mode of delivery (oral or injection).
At the study center, the usual practice was a starting dose of
intravenous or oral prednisone at 1 mg/kg per day for 2 to 4
weeks. Dosages are tapered within 8 to 12 weeks depending on
patient response comprising usually of prednisone dosage reduc-
tion of 5 mg/wk. The starting dose for budesonide was usually
9 mg/d, tapering with decrements of 3 mg over the course of 3 to
4 weeks. Using the dosage information and the duration of
treatment, we estimated the cumulative dosage of steroids for each
patient (dosage · duration for all episodes of steroid use through-
out the duration of the study interval). When corticosteroids other
than prednisone were administered (hydrocortisone, methylpred-
nisolone), we used reported conversion tables to convert all
steroids to prednisone with the exception of budesonide.17 For
the purpose of our study, we considered budesonide in a 1:1 ratio
compared with prednisone.
We abstracted steroid data both from the gastroenterology
clinic and any other department that the child may have visited
(e.g., the emergency department resulting from a disease ﬂare).
For some patients, steroid dosage modiﬁcations were made over
phone by the consulting gastroenterologist. We abstracted such
dosage modiﬁcations as well. Similar information was collected
for all steroid courses.
Assessment of Growth Impairment
Temporary Impairment
For each visit of the child, we abstracted the date of visit
and recorded height (centimeter) before disease diagnosis (where
available) at the time of disease diagnosis, before and subsequent
to steroid commencement, till the last reported visit. Based on this
information, we estimated the height of each individual at
different ages. Height z scores were than estimated using the
WHO 2007 reference values18 for each age separately for gender.
Z-scores ,21.64 (corresponding to the ﬁfth percentile of the
reference population height distribution) were used as the cutoff.
To compare results with previous studies,9,19,20 a z score of
,21.64 on more than 1 measurement was required for classiﬁ-
cation to the growth impairment phenotype.
Permanent Impairment
All patients who had completed 19 years of age at the time
of the start of the study (2011) were contacted to acquire their
ﬁnal adult height. Similarly, their parents were contacted to
acquire their heights. The target height for the patient was
estimated as follows:
For boys: {paternal height (centimeter) + (maternal height
[centimeter] +13)}/2;
For girls: {paternal height (centimeter) + (maternal height
[centimeter] 213)}/2.
Patients with adult heights 8.5 cm below the target height
were considered as not having achieved their expected adult
heights and deemed permanently growth impaired.21
To compare ﬁndings related to adult height from our study
to those within steroid users and nonusers of an independent
population, we analyzed data from a recent study22 that was based
on the Swiss IBD Cohort Study. Data from this study were
acquired on the subset of individuals who were diagnosed with
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CD during childhood (,18 yr of age). Data on gender, age at
diagnosis, whether administered steroids or not, age when ﬁnal
height was measured, and ﬁnal adult height measures (centimeter)
were acquired. We included only those patients whose ﬁnal adult
height was measured after age 19. To estimate ﬁnal adult height
z scores, we used the data provided by the Swiss Federal Ofﬁce of
Public Health Survey of 2007.23 Parental heights were, however,
not available for this study.
The institutional ethical board approved the study and
consent was acquired from the patients.
Statistical Analyses
Analysis was restricted to growth impairment that occurred
subsequent to steroid administration. Thus, all patients who had
height z scores ,1.64 on more than 1 occasion before the date of
administration of steroids were excluded from the study. For the
eligible children, the frequency of TGI and PGI along with their
95% conﬁdence intervals (CIs) was estimated assuming a binomial
distribution. Univariate analyses included comparing the distribu-
tion of relevant clinical and socio-demographic variables between
growth impaired and nonimpaired children. For continuous vari-
ables, such as age at diagnosis, age at steroid administration, and
cumulative steroid dose, tertiles were created using the entire
cohort. Single variable unconditional logistic regression models
were ﬁt to estimate the univariate associations. To examine mul-
tivariate associations, variables that seemed associated with TGI
in the univariate analysis (P values, 0.10) were entered a logistic
regression model. Potential multicollinearity between variables
was gauged by estimating variance inﬂation factors using the
“collin” command in STATA (Stata Statistical Software: Release
10.1.; StataCorp, College Station, TX). Odds ratios (OR) and 95%
CI were estimated.
To examine the predictors of ﬁnal adult height, a linear
regression model was ﬁt to the data. Both univariate and
multivariate regression analyses was performed. Beta coefﬁcients
(along with their 95% CI) and P values were estimated for each
predictor.
To assess temporal trends in growth impairment, a stratiﬁed
analysis was performed with stratiﬁcation coinciding with the
change in CD management over time (increasing use of immune-
modulators and introduction of anti–tumor necrosis factor [TNF]
medication era, year 2000).
RESULTS
A total of 237 patients were studied. From these, 13 (5.5%)
had growth impairment before the administration of steroids,
leaving 224 patients for further analysis. Another 3 patients who
received steroids after the age of 18 were also excluded. The ﬁnal
analysis was based on 221 patients. The mean (6SD) age at
diagnosis was 12.4 (63.25) years (Table 1). The mean (6SD)
age at start of steroids was 12.7 (63.2) years. The mean (6SD)
duration of follow-up since diagnosis was 1796 (61048.6) days.
There were more males (54.3%), and most patients were pubertal
(62.9%). The median (range) steroid dosage was 3697.5 mg (350–
51,757). Most patients had ileocolonic disease (60.2%) with the
inﬂammatory phenotype (89.1%). Disease severity according to
Harvey–Bradshaw index was mild–moderate in 57.5% of pa-
tients. Most patients were administrated concomitant medications
with approximately 10% patients diagnosed before year 2000
administered immune-modulators as compared with 50% among
those diagnosed subsequent to year 2000. Anti-TNF medication
was administered to 16 (7.2%) of the patients. Fifteen of these
children were diagnosed after year 2000. Family history of IBD
(ﬁrst-degree relatives) was reported in 10.4% of patients. Most
patients were of white ancestry (93.7%).
Approximately 19.0% (95% CI, 13–24) of the children
(42/221) had height z score of ,21.64 on .1 height measure.
Thus, the frequency was ;4 times greater than expected (5% of
normal and otherwise healthy children will have heights for age/
gender that are 1.64 SDs below the mean). Univariate analysis
(Table 2) suggested that early age at disease diagnosis (,11.6 yr
versus .14 yr; OR, 7.5; 95% CI, 2.1–26.7; P value 0.002) and
early age at steroid administration (,11.6 yr versus .15.9 yr; OR,
6.8; 95% CI, 2.2–21.1; P value 0.001) were associated with
increased risk for TGI. There were suggestions that children who
were prepubertal were more likely to be growth impaired (OR,
1.71; 95% CI, 0.87–3.38), but this association was not statistically
signiﬁcant (P value¼ 0.12). There were suggestions that increasing
cumulative dose of steroids was associated with increasing risk for
growth impairment (highest tertile versus lowest; OR, 1.6; 95% CI,
0.7–3.8); however, no clear trends were observed (P value for trend
.0.05). Patients who had concomitant or disease limited only to
the upper tract had slightly higher rates of growth impairment
(21.3%) compared with those without (18.1%), but these
differences were not statistically signiﬁcant. No other clinical or
socio-demographic variable seemed to be associated with growth
impairment. Stratiﬁcation on the year of diagnosis (before and after
2000), the rates of TGI were higher in the pre-2000 era (25.2%
versus 14.9%). These differences correspond with an increasing use
of immune-modulators in the post-2000 era (10% versus 50%). In
multivariate analysis (Table 3), associations only with age at steroid
start were evident. Compared to children who were administered
steroids after age 14, children administered steroids earlier (,11.6
yr; OR, 5.4; 95% CI, 1.7–17.1; P value 0.004 and 11.8–14 yr; OR,
6.9; 95% CI, 2.2–21.6; P value 0.001) were signiﬁcantly at higher
risks for growth impairment. There was no evidence of multicolli-
nearity (variance inﬂation factor ;5.0) between cumulative steroid
dosage and age at steroid start.
For 137 children, information on ﬁnal adult height and
parental height was available. Of these, 8 patients (5.8%; 95% CI,
1.8–9.8) achieved adult heights that were 8.5 cm below that of
their target height. This rate amounted to a frequency that was
almost 2 times than the expected rate (3% of normal and other-
wise healthy individuals are expected to have adult heights that
are ,8.5 cm below their target heights). Using ﬁnal height
z scores, 7.3% of the patients (95% CI, 2.9–11.7) were below
the cutoff value (,21.64), suggesting a growth impairment rate
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that was ;1.5 greater than expected (5% or normal children are
expected to have heights below the cutoff of 21.64 SD). On
univariate analysis, gender, puberty, and target height were asso-
ciated with ﬁnal adult height (Table 4). No associations between
increasing steroid dosage and ﬁnal adult height were evident. On
multivariate analysis, only target height was associated with ﬁnal
adult height (Table 4). For the Swiss cohort, 119 subjects were
eligible for analysis, of which 44 (37%) were administered ste-
roids and 75 (63.0%) had not been administered steroids. Based
on ﬁnal adult height z scores, 4 patients (9.1%; 95% CI, 3.4–21.1)
among those who were administered steroids and 2 patients
(2.7%; 95% CI, 0.7–9.2) among those who had never been admin-
istered steroids had z scores below the cutoff. After accounting for
normal expectations, the rate of growth impairment was ;2 times
higher among steroid users, whereas there was no evidence for
PGI among steroid nonusers.
DISCUSSION
In a well-characterized cohort of pediatric patients with CD
administered corticosteroids, we observed that approximately
19% of children were at risk for TGI and between 5.8% (based
on expected target height) and 7.3% (based only on ﬁnal adult
heights) of children were at risk for PGI. In the Swiss IBD cohort,
9.1% of steroid users and 2.7% were deemed as permanently
growth impaired based on ﬁnal adult height measures, not
accounting for parental heights. These ﬁndings indicate that most
patients with TGI attain their target ﬁnal adult heights, that the
burden of PGI from steroid usage is higher than nonsteroid users,
and that the rates of PGI are ;1.5 to 2 times higher than those
expected in the normal population.
Administration of steroids at an early age was associated
with temporary impairment. Increasing steroid doses was, however,
TABLE 1. Characteristics of the Montreal Study
Population (N ¼ 221)
Characteristic Number (%)
Age at diagnosis (mean 6 SD) 12.4 (3.25)
Age at diagnosis
Tertile 1 (2–11.6 yr) 75 (33.9)
Tertile 2 (11.8–14 yr) 81 (36.6)
Tertile 3 (14.6–18 yr) 65 (29.4)
Age at steroid start (mean 6 SD) 12.7 (3.2)
Age at steroid start
Tertile 1 (2.7–11.6 yr) 74 (33.4)
Tertile 2 (13.1–14.5 yr) 74 (33.5)
Tertile 3 (15.9–17.8 yr) 73 (33.0)
Gender
Male 120 (54.3)
Female 101 (45.7)
Puberty
Prepubertal 82 (37.1)
Pubertal 139 (62.9)
Steroid dose (median, range) 3697.5 (350–51,757)
Steroid dose
Tertile 1 (350–2660 mg) 70 (31.7)
Tertile 2 (2670–5177.5 mg) 75 (33.9)
Tertile 3 (5180–51,757 mg) 76 (34.4)
Disease behaviora
Inﬂammatory (6P) 197 (89.1)
Stricturing/penetrating (6P) 24 (10.9)
Disease locationa
Ileal only 15 (6.8)
Ileal (6L4) 11 (5.0)
Colonic only 47 (21.3)
Colonic (6L4) 12 (5.4)
Ileocolonic only 98 (44.3)
Ileocolonic (6L4) 35 (15.8)
L4 only 3 (1.4)
Concomitant medicationsb
Before 2000
None 13 (14.3)
Immuno-modulators 9 (9.9)
5-aminosalicylic acid 69 (75.8)
After 2000
None 11 (9.7)
Immuno-modulators 58 (50.9)
5-aminosalicylic acid 45 (39.5)
Anti-TNF medication
No 205 (92.8)
Yes 16 (7.2)
Surgery
No 212 (95.9)
Yes 9 (4.1)
TABLE 1 (Continued )
Characteristic Number (%)
Disease activityc
Mild–moderate 127 (57.5)
Severe 94 (42.5)
Family history of IBDd
No 198 (89.6)
Yes 23 (10.4)
Ethnicity
Non-white 14 (6.3)
White 207 (93.7)
aDisease behavior and location classiﬁed according to the World Gastroenterology
Organization’s Montreal Classiﬁcation, L4, upper tract.
bConcomitant medications administered at the initiation of steroid therapy.
cBased on the modiﬁed Harvey–Bradshaw index.
dIBD in ﬁrst-degree relative.
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TABLE 2. Association Between Temporary Growth Impairment and Socio-demographic and Clinical
Characteristics in the Montreal Cohort: Univariate Analysis
Characteristic Growth Impaired, N (%) Normal Growth, N (%) Odds Ratio (95% CI) P
Age at diagnosis (tertiles)
T3 3 (7.1) 62 (34.6) Reference
T2 19 (45.2) 62 (34.6) 6.3 (1.8–22.5) 0.004
T1 20 (47.6) 55 (30.7) 7.5 (2.1–26.7) 0.002
Age at steroid start (tertiles)
T3 4 (9.5) 69 (38.6) Reference
T2 17 (40.5) 57 (31.8) 5.1 (1.6–16.1) 0.005
T1 21 (50.0) 53 (29.6) 6.8 (2.2–21.1) 0.001
Gender
Female 19 (45.2) 82 (45.8) Reference
Male 23 (54.8) 97 (54.2) 1.0 (0.52–2.0) 0.95
Puberty
Pubertal 22 (52.4) 117 (65.4) Reference
Prepubertal 20 (47.6) 62 (34.6) 1.71 (0.87–3.38) 0.12
Steroid dose (tertiles)
T1 10 (23.8) 60 (33.5) Reference
T2 16 (38.1) 59 (33.0) 1.6 (0.7–3.9) 0.27
T3 16 (38.1) 60 (33.5) 1.6 (0.7–3.8) 0.29
Disease behavior
Inﬂammatory 39 (92.9) 158 (88.2) Reference
Noninﬂammatory 3 (7.1) 21 (11.7) 1.7 (0.5–6.1) 0.40
Disease location
Ileal 6 (14.3) 23 (12.8) Reference
Colonic 10 (23.8) 49 (27.4) 0.8 (0.3–2.4) 0.67
Ileocolonic 26 (61.9) 107 (59.8) 0.9 (0.3–2.5) 0.89
Upper tracta
No 29 (18.1) 131 (81.9)
Yes 13 (21.3) 48 (78.7) 1.22 (0.59–2.54) 0.59
Concomitant medications
No 7 (16.7) 18 (10.1) Reference
Yes 35 (83.3) 161 (89.9) 0.6 (0.2–1.4) 0.23
Surgery
No 41 (97.6) 171 (95.5) Reference
Yes 1 (2.4) 8 (4.5) 0.5 (0.1–4.3) 0.55
Disease activity
Mild–moderate 23 (54.8) 104 (58.1) Reference
Severe 19 (45.2) 77 (41.9) 1.1 (0.6–2.3) 0.69
Family history
No 36 (85.7) 162 (90.5) Reference
Yes 6 (14.3) 17 (9.5) 1.6 (0.6–4.3) 0.36
Ethnicity
Non-white 2 (4.8) 12 (6.7) Reference
White 40 (95.2) 167 (93.3) 1.4 (0.3–6.7) 0.64
aIncludes patients who had disease limited to the upper tract only or in combination with other sites.
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not associated with temporary impairment. Most patients with
temporary impairment demonstrated catch-up growth and attained
their target adult height. Final adult heights of the patients were
associated with target heights, but not with steroid dosage.
Corticosteroids are the mainstay of therapy for pediatric-
onset CD. It could thus be surmised that long-term steroid
administration to children diagnosed with CD may hamper
growth. The growth-suppressive effects of corticosteroids are
believed to occur at different steps during the linear growth
process and intimately related to the growth hormone–insulin
factor 1 axis. Steroids impair the pulsatile release of growth hor-
mone altering its output.24,25 In addition, they reduce growth hor-
mone receptor expression, hepatic growth hormone receptor
binding, growth hormone receptor mRNA levels, and plasma lev-
els of growth hormone-binding protein in a dose-dependent fash-
ion.26 Similarly, the activity of insulin growth factor 1 falls within
hours of steroid administration.27 This decreased activity is related
to a concurrent increase in the insulin growth factor binding pro-
tein 3 protein levels suggesting that steroid administration reduces
the bioavailability of insulin growth factor 1.28,29 This in turn can
lead to reduced proliferation of chondrocytes and delayed epiph-
yseal maturation, leading to growth suppression.
Although a biological link between steroids and growth
impairment is known,30 it is unclear whether steroids administra-
tion in children with CD impairs growth. For example, in a pro-
spective study in 69 children with IBD, Motil et al6 serially
monitored height for 3 years. Steroid therapy was recorded at
the time of entry into the study. Although there were deﬁcits in
linear growth, these deﬁcits were found to be associated with
disease activity but not with steroid therapy. These ﬁndings were
supported by 2 subsequent studies. Sentongo et al31 in a study
based on 132 children with CD reported no association between
lifetime steroid exposure and growth impairment in their cohort.
Similarly, Wine et al32 in a cohort of 93 patients with CD reported
associations of growth impairment with disease severity but not
with steroid therapy. Similarly, Lee et al9 in a prospective study
did not observe any association between steroid use and growth
impairment. In contrast to these ﬁndings, Markowitz et al5
observed that children with CD and PGI were administered steroids
for a longer duration. Alemzadeh et al8 reported that steroid use
during puberty was associated with a lower adult height. In a recent
prospective study, Pfefferkorn et al19 (n ¼ 176) reported that cor-
ticosteroid use for greater than 6 months in the ﬁrst year was
associated with abnormal height velocity at 1 year after adjusting
for disease severity. At 2 years, however, those with sustained use
of corticosteroids during the ﬁrst year, but discontinuation in year 2,
showed improvements in height velocities at year 2. As the adult
heights were not ascertained, it was not clear whether corticosteroid
use was associated with permanent effects on growth in this study.
Our study provides further support for a lack of association
between cumulative steroid use and growth impairment. The rates
of temporary impairment (19%) are similar to those reported
recently by Lee et al (21%)9 in their prospective study. Interest-
ingly, ;90% of their cohort was administered steroids. Although
they did not evaluate detailed steroid usage, in their study, chil-
dren who used steroids were not found to be more likely to be
growth impaired (temporary) and steroid use was not associated
with ﬁnal adult height. The rates of PGI (based on ﬁnal adult
height) were also comparable (7.3% in the Montreal cohort and
9.1% in the Swiss cohort) with those reported by Lee et al9
(11.3%). Rates of PGI estimated in the Montreal cohort (5.8%)
could not be compared as they could not be estimated in the Swiss
cohort and were not reported in the study of Lee et al.9
It is interesting to note that the rates of growth impairment
(in particular PGI) we observed were considerably lower than
those reported in CD cohorts examined in the 1990s and early
2000. Treatment of patients with CD had evolved considerably
during the last decade with the addition of immuno-modulators
and anti-TNF antibodies. These treatments are likely to have
modiﬁed the growth phenotype and contributed to the lower
frequencies currently observed. Toward this end, TNF-a antibod-
ies have been shown to promote growth in children with CD
diagnosed with TGI.33 Approximately 7% of our cohort was
administered biologics and comprised mostly patients diagnosed
after year 2000, and this may have contributed to the low rates of
growth impairment observed. Similarly, the use of immune-
modulators has dramatically increased subsequent to year 2000
and could have contributed as well. It is nonetheless important to
note that the rates of PGI observed in our Montreal and Swiss
steroid cohorts were ;2 times higher than those expected in
normal individuals. Furthermore, in the Swiss cohort of nonste-
roid users, there was no evidence of an increase in rates above
those normally expected. This would suggest that patients who are
administered steroids are at greater risk for PGI (as compared to
those not administered steroids and the normal population), but
this does not seem to be related to cumulative steroid usage.
Although the lack of variability in disease activity may have pre-
cluded adequate exploration of the link between disease activity
and growth impairment in our Montreal cohort, overall steroids
are mainly prescribed to children with moderate–severe disease
TABLE 3. Association Between Temporary Growth
Impairment and Socio-demographic and Clinical
Characteristics in the Montreal Cohort: Multivariate
Logistic Regression Analysis
Characteristic Odds Ratio (95% CI) P
Age at steroid start
T3 Reference
T2 5.4 (1.7–17.1) 0.004
T1 6.9 (2.2–21.6) 0.001
Steroid dose
T1 Reference
T2 1.7 (0.7–4.2) 0.24
T3 1.3 (0.5–3.2) 0.56
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activity and thus disease activity per se rather than steroid use may
be related to PGI. The latter is supported by the observed non-
increase in rates of PGI in the Swiss cohort of children not admin-
istered with steroids. By and large, such patients have milder
disease activity and hence do not necessitate the administration
of steroids. These observations remain speculative at this time and
require further clariﬁcation through additional, in particular, lon-
gitudinal data.
TABLE 4. Association Between Final Adult Height and Clinical and Demographic Characteristics in the Montreal
Cohort (Univariate and Multivariatea Linear Regression Analyses)
Characteristic Univariate b-coefﬁcient (95% CI) P Multivariate b-coefﬁcient (95% CI) P
Age at diagnosis (tertiles)
T3 Reference
T2 2.53 (21.18 to 6.25) 0.18
T1 3.35 (20.48 to 7.19) 0.09
Age at steroid start (tertiles)
T3 Reference
T2 1.41 (22.27 to 5.09) 0.45
T1 2.41 (21.37 to 6.18) 0.21
Gender
Female Reference
Male 12.74 (10.5 to 15.0) ,0.001 2.37 (20.37 to 5.10) 0.09
Puberty
Pubertal Reference
Prepubertal 23.87 (27.04 to 20.69) 0.018 20.58 (22.46 to 1.30) 0.54
Steroid dose (tertiles)
T1 Reference
T2 20.36 (24.23 to 3.50) 0.85 0.22 (21.90 to 2.33) 0.84
T3 0.81 (23.01 to 4.64) 0.67 0.76 (21.39 to 2.91) 0.49
Disease behavior
Inﬂammatory Reference
Noninﬂammatory 3.58 (21.06 to 8.22) 0.13
Disease location
Ileal Reference
Colonic 22.85 (28.21 to 2.51) 0.29
Ileocolonic 22.24 (27.03 to 2.55) 0.36
Concomitant medications
No Reference
Yes 20.40 (24.86 to 4.06) 0.86
Surgery
No Reference
Yes 25.06 (211.58 to 1.46) 0.13
Disease activity
Mild–moderate Reference
Severe 20.37 (23.48 to 2.73) 0.81
Family history
No Reference
Yes 21.10 (26.36 to 4.16) 0.68
Ethnicity
Non-white Reference
White 1.97 (28.56 to 12.50) 0.71
Target height 0.89 (0.79 to 0.99) ,0.001 0.79 (0.63 to 0.96) ,0.001
aOnly characteristics that are statistically signiﬁcant (P value , 0.05) were included in the multivariate analysis, which also included the steroid dosage variable.
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The retrospective nature of our study may have introduced
bias, in particular, in the ascertainment of the height measures. To
avoid misclassiﬁcation, only children with .1 height z score
,1.64 during follow-up were classiﬁed as temporarily growth
impaired. Adult height was directly acquired from the patients
and their parents. Although based on self-report, we do not antic-
ipate major misclassiﬁcation as height measures based on
self-report have been shown to be reliable.8,34–36 Height velocity
measures may be more representative of temporal growth changes,
but the retrospective nature of our study made ascertaining them for
all patients difﬁcult. To our knowledge, there are no dosage con-
versions for budesonide to prednisone. We considered their doses
to be equivalent. This strategy may have led to potential misclas-
siﬁcation in total steroid dosage. However, analyses of the data
after excluding doses of budesonide did not reveal any differences
(data not shown). We thus believe that considering budesonide to
be equivalent to prednisone did not inﬂuence the ﬁnal results.
Sawczenko et al37 based on height measures at diagnosis previously
reported that the mean height z scores were signiﬁcantly (P value
,0.05) lower in children with jejunal (20.9) and esophageal
(20.6) disease. The relationship between height and jejunal dis-
ease, however, did not maintain signiﬁcance when the delay to
diagnosis was accounted for in a regression analysis. As we used
the Montreal classiﬁcation, we were unable to study associations
speciﬁcally between growth impairment and proximal small bowel
disease. We, however, did examine associations between diseases
involving the upper gastrointestinal tract (that included the jejunum
and esophagus) either in isolation or in combination with other sites
and did not ﬁnd any association either with TGI or with PGI.
Certainly, these associations need further investigation.
In conclusion, our study suggests that current treatment
modalities for CD in children have resulted in lowering the
frequency of, in particular, PGI even among those administered
steroids. Nonetheless, rates are much higher in steroid users as
compared with nonusers. Keeping in mind the other consequences
of long-term steroid usage in children with CD, its judicious usage
in the appropriate management of the disease is warranted.
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